Health Technologies

Reacta Healthcare appoints Kevin Hawkins as Head of Regulatory Affairs

Early-stage food allergy diagnostic company Reacta Healthcare has announced the appointment of industry executive Kevin Hawkins as Head of Regulatory Affairs.

Hawkins has extensive pharma industry leadership experience spanning R&D, regulatory affairs, analytical development and project leadership.

He previously served as Senior Director and Head of Development at Teva Pharmaceuticals for over 10 years covering a broad range of R&D, analytical development and regulatory affairs.

Hawkins transitioned into Regulatory Affairs 15 years ago and subsequently built an R&D team at Teva with experience in multiple dosage form areas including inhalation, ophthalmic, parenteral and nasal sprays.

Reacta Healthcare CEO, Dr. Paul Abrahams, said: “We are delighted to welcome Kevin to the Reacta Senior Leadership Team at this critical juncture in the company’s development.

“Kevin is a highly skilled and respected senior leader with a strong track record in R&D and Regulatory Affairs.

“His experience in dealing with regulators and his practical approach to regulatory matters will be a great asset to Reacta and will be invaluable in contributing to the growth of the company.”

Reacta Healthcare is licenced to manufacture oral challenge meals for use in clinical trials, as auxiliary medicinal products.

The company’s challenge meals are currently used to diagnose and monitor food allergy in numerous global therapeutic trials.

The appointment will support Reacta Healthcare in its ongoing engagements with global health authorities as it seeks Marketing Authorisation (MA).

This will expand Reacta Healthcare’s market from the clinical research space to the broader commercial market of clinic based testing.

Hawkins’ background experience and expertise will be key to working collaboratively with the regulatory authorities to define the correct route to MA for the company’s orally consumed diagnostic.

Kevin Hawkins said:

“I am thrilled to be joining Reacta at this critical time as the company progresses its regulatory strategy with Health Authorities globally.

“I look forward to supporting the Executive Team in their continued efforts to build Reacta as a leading food allergy diagnostics company seeking to improve the lives of food allergy sufferers.”



About Author

You may also like

Health Technologies

Accelerating Strategies Around Internet of Medical Things Devices

  • December 22, 2022
IoMT Device Integration with the Electronic Health Record Is Growing By their nature, IoMT devices are integrated into healthcare organizations’
Health Technologies

3 Health Tech Trends to Watch in 2023

Highmark Health also uses network access control technology to ensure computers are registered and allowed to join the network. The